Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Clear Secure Inc (YOU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Clear Secure Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Clear Secure Inc trades at $54.42 (market cap $5.39B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is the larger of the two by market cap, and Clear Secure Inc pays a 1.12% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | YOU | |
|---|---|---|
Market Cap | $8.04B | $5.39B |
Sector | Health | Technology |
52-Week High | $339.75 | $62.36 |
52-Week Low | $241.71 | $28.84 |
Enterprise Value | $7.85B | $4.71B |
Dividend Yield | — | 1.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Clear Secure (YOU) trades at $53.08, down 3.88% on the day, with technical indicators showing bearish momentum. The company demonstrates strong fundamentals with 65.48% gross margins and impressive 81.15% ROE. Recent Q1 2026 earnings beat expectations at $0.38 EPS versus $0.35 expected, while analysts maintain a mixed consensus with 44% buy ratings and a $56.67 price target. The company continues expanding its airport security services with recent launches in Indianapolis and Miami.
YOU presents a compelling growth story with expanding revenue and profitability, though elevated valuation multiples (P/E 42.83) warrant caution. Near-term catalysts include Q2 earnings and continued airport expansion, while risks involve execution challenges and market volatility. The stock offers potential upside to analyst targets but requires monitoring of earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Clear Secure Inc
Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →
